Ronald Simon

List of Publications by Year in descending order

413 papers	21,889 citations	13827 67 h-index	14702 127 g-index
422 all docs	422 docs citations	422 times ranked	27021 citing authors

#	Article	IF	Citations
1	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	13.5	2,435
2	Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature, 2000, 406, 536-540.	13.7	1,877
3	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics, 2007, 39, 655-660.	9.4	351
4	Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. British Journal of Cancer, 2006, 94, 128-135.	2.9	327
5	Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer. Cancer Research, 2004, 64, 8534-8540.	0.4	306
6	Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer. Cancer Cell, 2013, 23, 159-170.	7.7	292
7	Comparative genomic hybridization of ductal carcinomain situ of the breast?evidence of multiple genetic pathways. , 1999, 187, 396-402.		291
8	Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer. Journal of the National Cancer Institute, 2001, 93, 1141-1146.	3.0	284
9	Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer. American Journal of Pathology, 2012, 181, 401-412.	1.9	278
10	ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy. Clinical Cancer Research, 2011, 17, 5878-5888.	3.2	232
11	High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer. Prostate, 2011, 71, 281-288.	1.2	224
12	Intratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer. Cell Reports, 2014, 8, 798-806.	2.9	219
13	Prevalence of KIT Expression in Human Tumors. Journal of Clinical Oncology, 2004, 22, 4514-4522.	0.8	212
14	Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2016, 69, 592-598.	0.9	212
15	Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. , 1999, 189, 521-526.		211
16	High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer. Breast Cancer Research and Treatment, 2004, 86, 207-213.	1.1	211
17	HER-2 amplification is highly homogenous in gastric cancer. Human Pathology, 2009, 40, 769-777.	1.1	194
18	The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Research and Treatment, 2006, 97, 275-283.	1.1	193

#	Article	IF	Citations
19	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell, 2018, 34, 996-1011.e8.	7.7	190
20	*CHD1* Is a 5q21 Tumor Suppressor Required for *ERG* Rearrangement in Prostate Cancer. Cancer Research, 2013, 73, 2795-2805.	0.4	188
21	Clinical significance of p53 alterations in surgically treated prostate cancers. Modern Pathology, 2008, 21, 1371-1378.	2.9	180
22	Tissue microarrays in drug discovery. Nature Reviews Drug Discovery, 2003, 2, 962-972.	21.5	178
23	Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nature Medicine, 2009, 15, 674-681.	15.2	172
24	Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Modern Pathology, 2007, 20, 120-129.	2.9	171
25	SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. Journal of Clinical Investigation, 2011, 121, 4257-4267.	3.9	153
26	Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. Journal of Pathology, 2001, 194, 165-170.	2.1	148
27	Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer. Clinical Cancer Research, 2007, 13, 6579-6584.	3.2	144
28	Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates. Cancer Research, 2006, 66, 2328-2337.	0.4	143
29	Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene, 2002, 21, 2476-2483.	2.6	142
30	E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene, 2004, 23, 5616-5623.	2.6	141
31	BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nature Genetics, 2015, 47, 22-30.	9.4	141
32	Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Laboratory Investigation, 2004, 84, 465-478.	1.7	134
33	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. , 1998, 185, 345-351.		129
34	Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate, 2009, 69, 976-981.	1.2	129
35	TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer, 2011, 11, 507.	1.1	128
36	Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene, 2007, 26, 5680-5691.	2.6	127

#	Article	IF	Citations
37	Genome-wide DNA Methylation Events in *TMPRSS2–ERG* Fusion-Negative Prostate Cancers Implicate an EZH2-Dependent Mechanism with *miR-26a* Hypermethylation. Cancer Discovery, 2012, 2, 1024-1035.	7.7	127
38	Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Modern Pathology, 2013, 26, 975-983.	2.9	127
39	Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer. Clinical Cancer Research, 2010, 16, 1553-1560.	3.2	125
40	High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Research, 2001, 61, 4514-9.	0.4	120
41	Chromosome *8p* Deletions and *8q* Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer. Clinical Cancer Research, 2010, 16, 56-64.	3.2	119
42	The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors. Clinical Cancer Research, 2011, 17, 2919-2933.	3.2	118
43	Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive *ERG* fusion-positive prostate cancers. Journal of Pathology, 2013, 231, 130-141.	2.1	118
44	Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies. Cancer Research, 2011, 71, 1362-1373.	0.4	117
45	High Ki67 expression is an independent good prognostic marker in colorectal cancer. Journal of Clinical Pathology, 2016, 69, 209-214.	1.0	114
46	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. Cancers, 2019, 11, 835.	1.7	109
47	HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. Journal of Clinical Pathology, 2006, 60, 768-772.	1.0	103
48	Influence of slide aging on results of translational research studies using immunohistochemistry. Modern Pathology, 2004, 17, 1414-1420.	2.9	102
49	High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. European Journal of Cancer, 2013, 49, 1273-1279.	1.3	101
50	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterology, 2015, 15, 7.	0.8	101
51	Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. International Journal of Cancer, 2006, 118, 2190-2194.	2.3	100
52	Mitochondrial mutations drive prostate cancer aggression. Nature Communications, 2017, 8, 656.	5.8	100
53	Tissue microarrays. BioTechniques, 2004, 36, 98-105.	0.8	99
54	KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT Gene Mutations. Clinical Cancer Research, 2004, 10, 178-183.	3.2	97

#	Article	IF	Citations
55	Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder. Clinical Cancer Research, 2005, 11, 4415-4429.	3.2	97
56	Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Experimental Hematology, 2002, 30, 1365-1372.	0.2	96
57	RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. International Journal of Cancer, 2013, 132, 2118-2126.	2.3	95
58	Clinical significance of different types of <i>p53</i> gene alteration in surgically treated prostate cancer. International Journal of Cancer, 2014, 135, 1369-1380.	2.3	95
59	HER-2 andTOP2A coamplification in urinary bladder cancer. International Journal of Cancer, 2003, 107, 764-772.	2.3	93
60	COMPARATIVE GENOMIC HYBRIDIZATION (CGH) ANALYSIS OF NEUROBLASTOMASâ€"AN IMPORTANT METHODOLOGICAL APPROACH IN PAEDIATRIC TUMOUR PATHOLOGY. , 1997, 181, 394-400.		91
61	Expression and Prognostic Relevance of Annexin A3 in Prostate Cancer. European Urology, 2008, 54, 1314-1323.	0.9	91
62	Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Research, 2001, 61, 355-62.	0.4	90
63	Random forest-based modelling to detect biomarkers for prostate cancer progression. Clinical Epigenetics, 2019, 11, 148.	1.8	89
64	Loss of <i>CHD1</i> causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Reports, 2016, 17, 1609-1623.	2.0	88
65	Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma. Cancer Research, 2004, 64, 1632-1638.	0.4	87
66	Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. Journal of Pathology, 2002, 197, 575-581.	2.1	86
67	High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. Journal of Pathology, 2003, 201, 603-608.	2.1	84
68	Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Human Pathology, 2010, 41, 1577-1585.	1.1	79
69	Intratumoral <scp>T</scp> but not <scp>B</scp> lymphocytes are related to clinical outcome in prostate cancer. Apmis, 2012, 120, 901-908.	0.9	77
70	Recipient Block TMA Technique. Methods in Molecular Biology, 2010, 664, 37-44.	0.4	73
71	Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers. PLoS ONE, 2013, 8, e54873.	1.1	70
72	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Modern Pathology, 2014, 27, 1612-1620.	2.9	69

#	ARTICLE	IF	CITATIONS
73	KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer, 2012, 107, 1997-2004.	2.9	68
74	Immunohistochemical Analysis of Tissue Microarrays. Methods in Molecular Biology, 2010, 664, 113-126.	0.4	68
75	Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 193-200.	1.4	67
76	Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: A tissue microarray study. International Journal of Cancer, 2002, 100, 702-705.	2.3	65
77	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. Neoplasia, 2017, 19, 707-715.	2.3	65
78	Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology, 2000, 37, 411-419.	1.6	63
79	Comparative genomic hybridization in pineal parenchymal tumors. Genes Chromosomes and Cancer, 2001, 30, 99-104.	1.5	62
80	Tissue microarrays in cancer diagnosis. Expert Review of Molecular Diagnostics, 2003, 3, 421-430.	1.5	62
81	Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. International Journal of Oncology, 2004, 25, 641.	1.4	62
82	Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients. Clinical Cancer Research, 2008, 14, 7838-7842.	3.2	62
83	Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2010, 123, 757-765.	1.1	62
84	MMSET Is Highly Expressed and Associated with Aggressiveness in Neuroblastoma. Cancer Research, 2011, 71, 4226-4235.	0.4	62
85	Marked heterogeneity of ERG expression in large primary prostate cancers. Modern Pathology, 2013, 26, 106-116.	2.9	62
86	Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Modern Pathology, 2007, 20, 192-198.	2.9	60
87	Loss of Reelin Expression in Breast Cancer Is Epigenetically Controlled and Associated with Poor Prognosis. American Journal of Pathology, 2010, 177, 2323-2333.	1.9	60
88	The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer. Oncogene, 2017, 36, 4124-4134.	2.6	60
89	Predominance of high-grade pathway in breast cancer development of Middle East women. Modern Pathology, 2005, 18, 891-897.	2.9	59
90	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. European Urology, 2018, 74, 376-386.	0.9	58

#	ARTICLE	IF	CITATIONS
91	Sequence analysis and high-throughput immunhistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 741-744.	1.4	57
92	Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in human neoplasms: a multitumour array analysis. British Journal of Cancer, 2013, 109, 1848-1858.	2.9	56
93	PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget, 2017, 8, 65566-65576.	0.8	56
94	Proteomic Profiling of Mammary Carcinomas Identifies C7orf24, a Î³-Glutamyl Cyclotransferase, as a Potential Cancer Biomarker. Journal of Proteome Research, 2010, 9, 3941-3953.	1.8	55
95	MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using largeâ€scale tissue microarrays. International Journal of Cancer, 2013, 133, 920-928.	2.3	55
96	Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion. Journal of Thoracic Oncology, 2011, 6, 199-202.	0.5	54
97	TMPRSS2-ERG Fusions Are Strongly Linked to Young Patient Age in Low-grade Prostate Cancer. European Urology, 2014, 66, 978-981.	0.9	54
98	Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. Scientific Reports, 2018, 8, 3947.	1.6	54
99	Prevalence of Î²III-tubulin (TUBB3) expression in human normal tissues and cancers. Tumor Biology, 2017, 39, 101042831771216.	0.8	51
100	Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. Carcinogenesis, 2017, 38, 19-27.	1.3	51
101	High mitochondria content is associated with prostate cancer disease progression. Molecular Cancer, 2013, 12, 145.	7.9	50
102	IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncology Reports, 2018, 39, 3-12.	1.2	50
103	Role of TP53 Mutations in Vulvar Carcinomas. International Journal of Gynecological Pathology, 2011, 30, 497-504.	0.9	49
104	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer, 2012, 118, 1268-1275.	2.0	48
105	Î²III-Tubulin Overexpression Is an Independent Predictor of Prostate Cancer Progression Tightly Linked to ERG Fusion Status and PTEN Deletion. American Journal of Pathology, 2014, 184, 609-617.	1.9	48
106	Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. International Journal of Oncology, 2014, 44, 609-615.	1.4	48
107	Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Carcinogenesis, 2015, 36, 1333-1340.	1.3	48
108	Reply to â€œESR1 gene amplification in breast cancer: a common phenomenon?â€• Nature Genetics, 2008, 40, 810-812.	9.4	47

#	Article	IF	Citations
109	High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Molecular Oncology, 2013, 7, 1001-1011.	2.1	47
110	Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. Disease Markers, 2019, 2019, 1-13.	0.6	47
111	Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Modern Pathology, 2012, 25, 1566-1573.	2.9	46
112	Tissue Microarrays. , 2005, 114, 257-268.		45
113	Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer. Molecular and Cellular Proteomics, 2010, 9, 161-177.	2.5	45
114	THSD7A expression in human cancer. Genes Chromosomes and Cancer, 2017, 56, 314-327.	1.5	45
115	Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer, 2010, 10, 295.	1.1	44
116	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. Nature Communications, 2020, 11, 139.	5.8	44
117	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. Oncotarget, 2015, 6, 8377-8387.	0.8	44
118	The apoptosis linked gene ALG‑2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Molecular Oncology, 2008, 1, 431-439.	2.1	43
119	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. Clinical Cancer Research, 2015, 21, 3471-3479.	3.2	43
120	CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clinical Oral Investigations, 2014, 18, 269-276.	1.4	42
121	Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. Biomedicines, 2021, 9, 397.	1.4	42
122	E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene, 2006, 25, 6538-6543.	2.6	41
123	Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer. Breast Cancer Research and Treatment, 2013, 137, 745-753.	1.1	41
124	Marked Gene Transcript Level Alterations Occur Early During Radical Prostatectomy. European Urology, 2008, 53, 333-346.	0.9	40
125	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2018, 73, 674-683.	0.9	40
126	The Multifunctional Growth Factor Midkine Promotes Proliferation and Migration in Pancreatic Cancer. Molecular Cancer Research, 2014, 12, 670-680.	1.5	39

#	ARTICLE	IF	CITATIONS
127	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. International Journal of Cancer, 2015, 137, 2354-2363.	2.3	39
128	High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer. Oncology Letters, 2016, 11, 1987-1994.	0.8	39
129	Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology, 2010, 42, 356-359.	0.3	38
130	Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer. Human Pathology, 2010, 41, 358-365.	1.1	38
131	SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate, 2013, 73, 1690-1698.	1.2	38
132	Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues. Disease Markers, 2019, 2019, 1-11.	0.6	38
133	Sef Downregulation by Ras Causes MEK1/2 to Become Aberrantly Nuclear Localized Leading to Polyploidy and Neoplastic Transformation. Cancer Research, 2012, 72, 626-635.	0.4	37
134	Loss of p^{Ser2448}–mTOR expression is linked to adverse prognosis and tumor progression in ERG–fusion–positive cancers. International Journal of Cancer, 2013, 132, 1333-1340.	2.3	37
135	Tissue Microarrays. Methods in Molecular Biology, 2016, 1381, 53-65.	0.4	37
136	Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Modern Pathology, 2013, 26, 733-742.	2.9	36
137	Reprogramming of the ERRα and ERα Target Gene Landscape Triggers Tamoxifen Resistance in Breast Cancer. Cancer Research, 2015, 75, 720-731.	0.4	36
138	Deletion of 8p is an independent prognostic parameter in prostate cancer. Oncotarget, 2017, 8, 379-392.	0.8	36
139	Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. Journal of Pathology, 2008, 216, 151-157.	2.1	35
140	Loss of protein expression and recurrent DNA hypermethylation of the GNG7 gene in squamous cell carcinoma of the head and neck. Journal of Applied Genetics, 2012, 53, 167-174.	1.0	35
141	High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition. Clinical Cancer Research, 2013, 19, 2331-2341.	3.2	35
142	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. Genes Chromosomes and Cancer, 2018, 57, 504-512.	1.5	35
143	Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. Journal of Pathology, 2002, 198, 115-120.	2.1	34
144	High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. European Journal of Cancer, 2014, 50, 852-861.	1.3	34

#	Article	IF	Citations
145	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. Oncotarget, 2015, 6, 12822-12834.	0.8	34
146	Tissue microarray (TMA) applications: implications for molecular medicine. Expert Reviews in Molecular Medicine, 2003, 5, 1-12.	1.6	33
147	PSMA Expression is Highly Homogenous in Primary Prostate Cancer. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 449-455.	0.6	33
148	Cyclin D1 gene amplification is highly homogeneous in breast cancer. Breast Cancer, 2016, 23, 111-119.	1.3	33
149	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomarker Research, 2021, 9, 7.	2.8	33
150	Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. Aging, 2019, 11, 7796-7804.	1.4	33
151	Predictive Molecular Pathology. New England Journal of Medicine, 2002, 347, 1995-1996.	13.9	32
152	High-throughput tissue microarray analysis ofCMYC amplificationin urinary bladder cancer. International Journal of Cancer, 2005, 117, 952-956.	2.3	32
153	AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 243-248.	1.4	32
154	Combined α-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. Human Pathology, 2009, 40, 166-173.	1.1	32
155	Immunohistochemical and <scp>FISH</scp> analysis of <scp>EGFR</scp> and its prognostic value in patients with oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2014, 43, 205-210.	1.4	32
156	Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. Molecular Medicine, 2021, 27, 16.	1.9	32
157	Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. BMC Medical Genetics, 2010, 11, 106.	2.1	31
158	The Relationship Between Annual Hospital Volume of Trauma Patients and In-Hospital Mortality in New York State. Journal of Trauma, 2011, 71, 339-346.	2.3	31
159	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. Cancer Letters, 2018, 423, 60-70.	3.2	31
160	IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans. Gastroenterology, 2020, 159, 1417-1430.e3.	0.6	31
161	p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget, 2016, 7, 81322-81331.	0.8	31
162	Decay-accelerating factor (CD55): A versatile acting molecule in human malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 42-52.	3.3	30

#	Article	IF	Citations
163	Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology, 2010, 57, 418-426.	1.6	30
164	Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome. Modern Pathology, 2010, 23, 603-610.	2.9	30
165	<i>EGFR</i>gene copy number increase in vulvar carcinomas is linked with poor clinical outcome. Journal of Clinical Pathology, 2012, 65, 133-139.	1.0	30
166	<i><scp>PTEN</scp></i> deletions are related to disease progression and unfavourable prognosis in early bladder cancer. Histopathology, 2013, 63, 670-677.	1.6	30
167	Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. Journal of Clinical Pathology, 2013, 66, 563-568.	1.0	30
168	The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. International Journal of Cancer, 2014, 135, 1399-1407.	2.3	30
169	Partial PTEN deletion is linked to poor prognosis in breast cancer. BMC Cancer, 2015, 15, 963.	1.1	30
170	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. BMC Cancer, 2015, 15, 538.	1.1	30
171	Reduced <scp>AZGP1</scp> expression is an independent predictor of early <scp>PSA</scp> recurrence and associated with ERG‑fusion positive and <scp><i>PTEN</i></scp> deleted prostate cancers. International Journal of Cancer, 2016, 138, 1199-1206.	2.3	30
172	High-Level Î³-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. International Journal of Molecular Sciences, 2017, 18, 286.	1.8	30
173	E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. Biomarker Research, 2021, 9, 44.	2.8	30
174	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget, 2015, 6, 27966-27979.	0.8	30
175	MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large-scale tissue microarrays. Journal of Mass Spectrometry, 2017, 52, 165-173.	0.7	29
176	Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers. Cellular Oncology (Dordrecht), 2021, 44, 793-803.	2.1	29
177	Tissue Microarrays. Methods in Molecular Biology, 2009, 576, 49-60.	0.4	29
178	Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer. Clinical Cancer Research, 2014, 20, 1791-1802.	3.2	28
179	Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma. BMC Cancer, 2018, 18, 1209.	1.1	28
180	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. Aging, 2019, 11, 7859-7879.	1.4	28

#	Article	IF	Citations
181	MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. Anticancer Research, 2014, 34, 2255-61.	0.5	28
182	Prognostic relevance of Bclâ€2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene. Prostate, 2012, 72, 991-997.	1.2	27
183	Immunohistochemical analysis of p16 expression, <scp>HPV</scp> infection and its prognostic utility in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2013, 42, 676-681.	1.4	27
184	MALDI imagingâ€"based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays1These authors contributed equally to this work.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1225-1233.	0.8	27
185	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. Prostate, 2016, 76, 259-272.	1.2	27
186	Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer. Scientific Reports, 2017, 7, 2056.	1.6	27
187	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. PLoS ONE, 2015, 10, e0128525.	1.1	26
188	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. Experimental and Molecular Pathology, 2015, 98, 419-426.	0.9	26
189	8p deletion is strongly linked to poor prognosis in breast cancer. Cancer Biology and Therapy, 2015, 16, 1080-1087.	1.5	26
190	Internal standardization of LA-ICP-MS immuno imaging via printing of universal metal spiked inks onto tissue sections. Journal of Analytical Atomic Spectrometry, 2016, 31, 801-808.	1.6	26
191	Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer. World Journal of Urology, 2018, 36, 877-882.	1.2	26
192	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. Oncotarget, 2017, 8, 108923-108935.	0.8	26
193	19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes and Cancer, 2010, 49, 569-575.	1.5	25
194	High nuclear karyopherin Î± 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Modern Pathology, 2014, 27, 96-106.	2.9	25
195	Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. Diagnostic Pathology, 2015, 10, 125.	0.9	25
196	Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients. BMC Cancer, 2016, 16, 641.	1.1	24
197	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. BMC Cancer, 2019, 19, 193.	1.1	24
198	High homogeneity of MMR deficiency in ovarian cancer. Gynecologic Oncology, 2020, 156, 669-675.	0.6	24

#	ARTICLE	IF	CITATIONS
199	Deletion of 18q is a strong and independent prognostic feature in prostate cancer. Oncotarget, 2016, 7, 86339-86349.	0.8	24
200	High intratumoral FOXP3â T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 8227-35.	0.5	24
201	Molecular Cancer Phenotype in Normal Prostate Tissue. European Urology, 2009, 55, 885-891.	0.9	23
202	MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer. Cancer Biomarkers, 2011, 8, 53-60.	0.8	23
203	Î² III-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. Human Pathology, 2017, 61, 210-220.	1.1	23
204	Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer. Scientific Reports, 2018, 8, 17535.	1.6	23
205	Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. Cellular Oncology (Dordrecht), 2020, 43, 421-430.	2.1	23
206	Microsatellite DNA Alterations of Gastrointestinal Stromal Tumors Are Predictive for Outcome. Clinical Cancer Research, 2006, 12, 5151-5157.	3.2	22
207	The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. International Journal of Oncology, 2011, 40, 261-8.	1.4	22
208	Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients. Oncology Reports, 2014, 32, 2628-2634.	1.2	22
209	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. Oncotarget, 2019, 10, 5439-5453.	0.8	22
210	Patterns of chromosomal imbalances in muscle invasive bladder cancer.. International Journal of Oncology, 2000, 17, 1025-9.	1.4	21
211	High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Human Pathology, 2006, 37, 453-457.	1.1	21
212	The Expression and Action of Decay-Accelerating Factor (CD55) in Human Malignancies and Cancer Therapy. Analytical Cellular Pathology, 2006, 28, 223-232.	0.7	21
213	Overexpression of the chromatin remodeler death-domainâ€"associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. Human Pathology, 2013, 44, 1789-1796.	1.1	21
214	<scp>MALDI</scp> imaging on largeâ€scale tissue microarrays identifies molecular features associated with tumour phenotype in oesophageal cancer. Histopathology, 2013, 63, 455-462.	1.6	21
215	Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. Lung Cancer, 2013, 79, 221-227.	0.9	21
216	Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncology Letters, 2013, 6, 1245-1252.	0.8	21

#	Article	IF	Citations
217	Loss of <scp>RNA</scp>â€binding motif protein 3 expression is associated with rightâ€sided localization and poor prognosis in colorectal cancer. Histopathology, 2016, 68, 191-198.	1.6	21
218	The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. Clinical Cancer Research, 2016, 22, 2802-2811.	3.2	21
219	Applications of Tissue Microarray Technology. Methods in Molecular Biology, 2010, 664, 1-16.	0.4	21
220	Tissue microarrays for high-throughput molecular pathology. Annals of Saudi Medicine, 2004, 24, 169-174.	0.5	21
221	Estrogen receptor gene amplification occurs rarely in ovarian cancer. Modern Pathology, 2009, 22, 191-196.	2.9	20
222	<i>PPFIA1</i> and <i>CCND1</i> are frequently coamplified in breast cancer. Genes Chromosomes and Cancer, 2010, 49, 1-8.	1.5	20
223	Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer. Human Pathology, 2013, 44, 1524-1533.	1.1	20
224	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. Tumor Biology, 2016, 37, 12655-12663.	0.8	20
225	16p13.11 microdeletion uncovers lossâ€ofâ€function of a <i>MYH11</i> missense variant in a patient with megacystisâ€microcolonâ€intestinalâ€hypoperistalsis syndrome. Clinical Genetics, 2019, 96, 85-90.	1.0	20
226	MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. Annals of Surgical Oncology, 2020, 27, 3997-4006.	0.7	20
227	Distinct Gene Expression Profiles: Nodal versus Extranodal Diffuse Large B-Cell Lymphoma. Oncology, 2008, 75, 71-80.	0.9	19
228	Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers. Pathology and Oncology Research, 2016, 22, 95-102.	0.9	19
229	Apurinic/apyrimidinic endonuclease 1 (APE1/Refâ€1) overexpression is an independent prognostic marker in prostate cancer without <i>TMPRSS2:ERG</i> fusion. Molecular Carcinogenesis, 2017, 56, 2135-2145.	1.3	19
230	PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. BMC Cancer, 2018, 18, 612.	1.1	19
231	p53 overexpression is a prognosticator of poor outcome in esophageal cancer. Oncology Letters, 2019, 17, 3826-3834.	0.8	19
232	Expression of CCCTCâ€binding factor (CTCF) is linked to poor prognosis in prostate cancer. Molecular Oncology, 2020, 14, 129-138.	2.1	19
233	MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 488-495.	0.8	19
234	Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. Human Pathology, 2021, 115, 19-36.	1.1	19

#	Article	IF	Citations
235	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. Oncotarget, 2020, 11, 237-249.	0.8	19
236	HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. International Journal of Oncology, 2004, 25, 1551-7.	1.4	19
237	Serum Midkine Correlates with Tumor Progression and Imatinib Response in Gastrointestinal Stromal Tumors. Annals of Surgical Oncology, 2011, 18, 559-565.	0.7	18
238	Diverse expression patterns of the <scp>EMT</scp> suppressor grainheadâ€like 2 (<scp>GRHL</scp>2) in normal and tumour tissues. International Journal of Cancer, 2016, 138, 949-963.	2.3	18
239	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. Human Pathology, 2016, 48, 102-110.	1.1	18
240	Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. Journal of Thoracic Oncology, 2018, 13, e243-e246.	0.5	18
241	Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas. American Journal of Surgical Pathology, 2022, 46, 97-104.	2.1	18
242	Tissue Microarrays. , 2004, 97, 377-390.		17
243	Epstein â€" Barr virus infection is not the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia. Leukemia and Lymphoma, 2006, 47, 707-713.	0.6	17
244	Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 483-490.	1.4	17
245	No Detection of XMRV in Blood Samples and Tissue Sections from Prostate Cancer Patients in Northern Europe. PLoS ONE, 2011, 6, e25592.	1.1	17
246	On the evidence for ESR1 amplification in breast cancer. Nature Reviews Cancer, 2012, 12, 149-149.	12.8	17
247	Upregulation of centromere protein F is linked to aggressive prostate cancers. Cancer Management and Research, 2018, Volume 10, 5491-5504.	0.9	17
248	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 531.e19-531.e25.	0.8	17
249	High homogeneity of mismatch repair deficiency in advanced prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 745-752.	1.4	17
250	High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer. International Journal of Colorectal Disease, 2020, 35, 259-268.	1.0	17
251	TIP5 primes prostate luminal cells for the oncogenic transformation mediated by <i>PTEN</i> -loss. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3637-3647.	3.3	17
252	High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East. Human Pathology, 2006, 37, 742-748.	1.1	16

#	Article	IF	Citations
253	HER-2/neu analysis in breast cancer bone metastases. Journal of Clinical Pathology, 2009, 62, 542-546.	1.0	16
254	PTEN deletion is rare but often homogeneous in gastric cancer. Journal of Clinical Pathology, 2012, 65, 693-698.	1.0	16
255	Role of cyclin D1 amplification and expression in vulvar carcinomas. Human Pathology, 2012, 43, 1386-1393.	1.1	16
256	Amplification of the PPFIA1 gene region on 11q13 in oral squamous cell carcinomas (OSCC). Journal of Cranio-Maxillo-Facial Surgery, 2013, 41, 845-849.	0.7	16
257	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. PLoS ONE, 2015, 10, e0134614.	1.1	16
258	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. Neoplasia, 2017, 19, 279-287.	2.3	16
259	High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. Prostate, 2017, 77, 1528-1538.	1.2	16
260	<scp>EZH</scp>2 overexpression in head and neck cancer is related to lymph node metastasis. Journal of Oral Pathology and Medicine, 2018, 47, 240-245.	1.4	16
261	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. BMC Cancer, 2018, 18, 37.	1.1	16
262	High B7-H3 expression is linked to increased risk of prostate cancer progression. Pathology International, 2020, 70, 733-742.	0.6	16
263	FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma. PLoS ONE, 2015, 10, e0141867.	1.1	16
264	Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. Oncology Letters, 2010, 1, 729-732.	0.8	15
265	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. Carcinogenesis, 2017, 38, 1180-1187.	1.3	15
266	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. Methods, 2017, 114, 60-73.	1.9	15
267	Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. Endocrine Pathology, 2020, 31, 182-189.	5.2	15
268	Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. Experimental and Molecular Pathology, 2022, 126, 104762.	0.9	15
269	Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. Pathobiology, 2022, 89, 245-258.	1.9	15
270	ESR1 Amplification in Breast Cancer by Optimized RNase FISH: Frequent but Low-Level and Heterogeneous. PLoS ONE, 2013, 8, e84189.	1.1	14

#	Article	IF	Citations
271	ẞIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. World Journal of Urology, 2015, 33, 1561-1569.	1.2	14
272	High‐level ẞIII‐tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome. Journal of Oral Pathology and Medicine, 2017, 46, 986-990.	1.4	14
273	A shift from membranous and stromal syndecan‐1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. Molecular Carcinogenesis, 2019, 58, 2306-2315.	1.3	14
274	Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers. Scientific Reports, 2020, 10, 8916.	1.6	14
275	Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. Oncotarget, 2020, 11, 1007-1016.	0.8	14
276	Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. Experimental and Molecular Pathology, 2013, 95, 227-234.	0.9	13
277	High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. Experimental and Therapeutic Medicine, 2013, 5, 102-106.	0.8	13
278	Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer. International Journal of Oncology, 2015, 46, 1637-1642.	1.4	13
279	Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. Cells, 2020, 9, 2337.	1.8	13
280	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. Cancer Biology and Medicine, 2021, 18, 245-255.	1.4	13
281	Y-chromosome loss is frequent in male renal tumors. Annals of Translational Medicine, 2021, 9, 209-209.	0.7	13
282	Expression and amplification of therapeutic target genes in retinoblastoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 156-162.	1.0	12
283	FISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context. Journal of Clinical Bioinformatics, 2011, 1, 20.	1.2	12
284	BIRC2 amplification in squamous cell carcinomas of the uterine cervix. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 123-128.	1.4	12
285	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. Oncology Reports, 2015, 34, 1211-1220.	1.2	12
286	Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. Disease Markers, 2019, 2019, 1-6.	0.6	12
287	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. BMC Cancer, 2020, 20, 1220.	1.1	12
288	Napsin A Expression in Human Tumors and Normal Tissues. Pathology and Oncology Research, 2021, 27, 613099.	0.9	12

#	ARTICLE	IF	CITATIONS
289	Pattern of placental alkaline phosphatase (<scp>PLAP</scp>) expression in human tumors: a tissue microarray study on 12,381 tumors. Journal of Pathology: Clinical Research, 2021, 7, 577-589.	1.3	12
290	Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer. Pathology, 2012, 44, 448-452.	0.3	11
291	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. World Journal of Urology, 2021, 39, 481-490.	1.2	11
292	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. International Urology and Nephrology, 2021, 53, 2493-2503.	0.6	11
293	Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 433-447.	1.4	11
294	Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin. Annals of Diagnostic Pathology, 2021, 54, 151793.	0.6	11
295	DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. Pathology Research and Practice, 2021, 228, 153663.	1.0	11
296	Tissue microarrays for early target evaluation. Drug Discovery Today: Technologies, 2004, 1, 41-48.	4.0	10
297	High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. International Journal of Oncology, 2005, 27, 385.	1.4	10
298	HER-2 amplification is highly homogenous in gastric cancer—reply. Human Pathology, 2010, 41, 305-306.	1.1	10
299	NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. Prostate, 2014, 74, 1012-1022.	1.2	10
300	Saccharomyces cerevisiae–like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion–positive and fusion-negative cancers. Human Pathology, 2015, 46, 514-523.	1.1	10
301	High expression of class III β–tubulin in upper gastrointestinal cancer types. Oncology Letters, 2018, 16, 7139-7145.	0.8	10
302	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. World Journal of Urology, 2020, 38, 2185-2196.	1.2	10
303	Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer. European Journal of Cancer, 2020, 137, 93-107.	1.3	10
304	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG–negative prostate cancer. Prostate, 2020, 80, 1097-1107.	1.2	10
305	MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10â€¦399 Tissue Samples. Technology in Cancer Research and Treatment, 2021, 20, 153303382110433.	0.8	10
306	High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. Acta OncolÃ³gica, 2021, 60, 1210-1217.	0.8	10

#	Article	IF	Citations
307	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. Oncotarget, 2017, 8, 31494-31508.	0.8	10
308	Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. Journal of King Abdulaziz University, Islamic Economics, 2006, 27, 323-8.	0.5	10
309	Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age. Prostate, 2012, 72, 898-903.	1.2	9
310	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. BMC Cancer, 2017, 17, 504.	1.1	9
311	Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome. BMC Cancer, 2018, 18, 1106.	1.1	9
312	The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. Tumor Biology, 2019, 41, 101042831882481.	0.8	9
313	Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer. Medical Molecular Morphology, 2021, 54, 156-165.	0.4	9
314	Upregulation of SPDEF is associated with poor prognosis in prostate cancer. Oncology Letters, 2019, 18, 5107-5118.	0.8	9
315	Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness. Biochemical and Biophysical Research Communications, 2005, 329, 318-323.	1.0	8
316	Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial–mesenchymal transition and PI3K alterations. Gynecologic Oncology, 2014, 134, 599-606.	0.6	8
317	Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays. Pathology and Oncology Research, 2015, 21, 1183-1189.	0.9	8
318	Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. Molecular Medicine Reports, 2016, 14, 1443-1450.	1.1	8
319	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 43.e13-43.e20.	0.8	8
320	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. Pathology International, 2020, 70, 441-451.	0.6	8
321	Immunoexpression Analysis and Prognostic Value of BLCAP in Breast Cancer. PLoS ONE, 2012, 7, e45967.	1.1	8
322	Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. Oncotarget, 2016, 7, 3897-3904.	0.8	8
323	High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy. Prostate Cancer and Prostatic Diseases, 2013, 16, 159-164.	2.0	7
324	Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma. Child's Nervous System, 2016, 32, 281-290.	0.6	7

#	Article	IF	Citations
325	Expression of the immune checkpoint receptor TIGIT in seminoma. Oncology Letters, 2019, 18, 1497-1502.	0.8	7
326	SNW1 is a prognostic biomarker in prostate cancer. Diagnostic Pathology, 2019, 14, 33.	0.9	7
327	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. Pathology and Oncology Research, 2020, 26, 2709-2722.	0.9	7
328	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. BioMed Research International, 2020, 2020, 1-13.	0.9	7
329	Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization. International Journal of Clinical and Experimental Pathology, 2015, 8, 7009-15.	0.5	7
330	PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power. Cancers, 2022, 14, 1267.	1.7	7
331	Angiotensin-Converting Enzyme 2 Protein Is Overexpressed in a Wide Range of Human Tumour Types: A Systematic Tissue Microarray Study on >15,000 Tumours. Biomedicines, 2021, 9, 1831.	1.4	7
332	P53 immunohistochemical expression does not correlate with clinical features in 207 carcinomas of the oral cavity and in the head and neck region. Clinical Oral Investigations, 2014, 18, 211-217.	1.4	6
333	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. Experimental and Molecular Pathology, 2018, 105, 50-56.	0.9	6
334	Hyperparameter optimization for image analysis: application to prostate tissue images and live cell data of virus-infected cells. International Journal of Computer Assisted Radiology and Surgery, 2019, 14, 1847-1857.	1.7	6
335	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 625-636.	1.4	6
336	Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, e29-e38.	0.6	6
337	Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. Cancer Investigation, 2021, 39, 711-720.	0.6	6
338	High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. Modern Pathology, 2006, 19, 1124-1129.	2.9	5
339	Patterns of ALK expression in different human cancer types. Journal of Clinical Pathology, 2014, 67, 477-481.	1.0	5
340	FISH Oracle 2: a web server for integrative visualization of genomic data in cancer research. Journal of Clinical Bioinformatics, 2014, 4, 5.	1.2	5
341	Reduced membranous MET expression is linked to bladder cancer progression. Cancer Genetics, 2014, 207, 147-152.	0.2	5
342	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. Neoplasia, 2019, 21, 872-881.	2.3	5

#	Article	IF	Citations
343	Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients. Cancer Medicine, 2020, 9, 1409-1418.	1.3	5
344	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. Molecular Medicine, 2020, 26, 24.	1.9	5
345	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. Pathology, 2020, 52, 421-430.	0.3	5
346	Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets. Molecular Oncology, 2021, 15, 1956-1969.	2.1	5
347	Prevalence of proliferating CD8+ cells in normal lymphatic tissues, inflammation and cancer. Aging, 2021, 13, 14590-14603.	1.4	5
348	Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a <i>ROS1</i> p.L1950F Mutation: Case Report. Oncology Research and Treatment, 2021, 44, 495-502.	0.8	5
349	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. Oncotarget, 2019, 10, 4973-4986.	0.8	5
350	Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence. Laboratory Investigation, 2022, 102, 650-657.	1.7	5
351	VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy. International Journal of Molecular Sciences, 2015, 16, 8591-8606.	1.8	4
352	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. BMC Cancer, 2019, 19, 944.	1.1	4
353	Loss of CCAATâ€enhancerâ€binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. Prostate, 2019, 79, 302-311.	1.2	4
354	5q21 deletion is often heterogeneous in prostate cancer. Genes Chromosomes and Cancer, 2019, 58, 509-515.	1.5	4
355	High RSF1 protein expression is an independent prognostic feature in prostate cancer. Acta Oncolǵgica, 2020, 59, 268-273.	0.8	4
356	Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. Clinical and Experimental Metastasis, 2020, 37, 649-656.	1.7	4
357	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer. Disease Markers, 2020, 2020, 1-10.	0.6	4
358	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusionâ€positive prostate cancers. International Journal of Cancer, 2020, 147, 575-583.	2.3	4
359	DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. PeerJ, 2021, 9, e11905.	0.9	4
360	Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion. Oncotarget, 2019, 10, 7096-7111.	0.8	4

#	ARTICLE	IF	CITATIONS
361	Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology. Human Pathology, 2022, 126, 108-120.	1.1	4
362	High concordance of findings obtained from transgluteal magnetic resonance imaging â€•and transrectal ultrasonographyâ€•guided biopsy as compared with prostatectomy specimens. BJU International, 2017, 120, 365-376.	1.3	3
363	Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer. Cancer Management and Research, 2018, Volume 10, 5909-5917.	0.9	3
364	High concordance of TMPRSSâ€‘ERG fusion between primary prostate cancer and its lymph node metastases. Oncology Letters, 2018, 16, 6238-6244.	0.8	3
365	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. World Journal of Surgical Oncology, 2020, 18, 128.	0.8	3
366	Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 605.e1-605.e8.	0.8	3
367	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. World Journal of Urology, 2021, 39, 829-837.	1.2	3
368	Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer. International Journal of Cancer, 2021, 148, 748-758.	2.3	3
369	Mismatch repair deficiency occurs very rarely in seminomas. Translational Andrology and Urology, 2021, 10, 1048-1055.	0.6	3
370	MUC5AC expression is linked to mucinous/endometroid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. Pathology Research and Practice, 2021, 224, 153533.	1.0	3
371	High mitochondrial content is associated with breast cancer aggressiveness. Molecular and Clinical Oncology, 2021, 15, 203.	0.4	3
372	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. Cancer Gene Therapy, 2022, 29, 49-61.	2.2	3
373	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. , 1998, 185, 345.		3
374	Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. Journal of Clinical Oncology, 2012, 30, 10501-10501.	0.8	3
375	<i><scp>HER</scp>2</i> amplification in squamous cell carcinomas of the vulva. Histopathology, 2013, 62, 965-967.	1.6	2
376	Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. Microarrays (Basel, Switzerland), 2014, 3, 137-158.	1.4	2
377	CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. Clinical Oral Investigations, 2017, 21, 1503-1508.	1.4	2
378	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of <i>PTEN</i> deleted prostate cancers. Cancer Biology and Medicine, 2019, 16, 319.	1.4	2

#	Article	IF	Citations
379	Ectopic Expression of Hematopoietic SHIP1 in Human Colorectal Cancer. Biomedicines, 2020, 8, 215.	1.4	2
380	Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. , 1999, 189, 521.		2
381	Abstract 696: Patterns of TIGIT expression in normal lymphatic tissue, inflammation and cancer. , 2018, , .		2
382	A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer. Oncotarget, 2019, 10, 1729-1744.	0.8	2
383	Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma. Diagnostics, 2021, 11, 2351.	1.3	2
384	HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis - reply. Human Pathology, 2011, 42, 910-911.	1.1	1
385	Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2879-2884.	1.2	1
386	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. , 1998, 185, 345.		1
387	Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways. , 1999, 187, 396.		1
388	6q deletion is frequent but unrelated to patient prognosis in breast cancer. Breast Cancer, 2021, , 1.	1.3	1
389	Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	1
390	Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211065.	1.0	1
391	Chromosomal Aberrations Associated With Invasion in Papillary Superficial Bladder Cancer. Journal of Urology, 1999, 162, 621-621.	0.2	0
392	Tissue Microarrays for Miniaturized High-Throughput Molecular Profiling of Tumors. Biological and Medical Physics Series, 2005, , 345-360.	0.3	0
393	Tissue microarrays. , 2005, , .		0
394	βIII-tubulin overexpression is linked to left-sided tumor localization and nuclear β-catenin expression in colorectal cancer. Cancer Treatment Communications, 2015, 4, 96-102.	0.4	0
395	Internationales Krebsgenomkonsortium (ICGC). Medizinische Genetik, 2017, 28, 416-423.	0.1	0
396	P03.01—...Prevalence of CD112R+immune cells in normal lymphatic tissues, inflammation and the cancer microenvironment. , 2020, 8, A22.1-A22.		0

#	Article	IF	Citations
397	P03.10â€¦Prevalence and prognostic role of FoxP3⁺regulatory T lymphocytes in cancer. A tissue microarray study on >20â€™000 cancers. , 2020, , .		0
398	P03.06â€¦Pattern of Ki67⁺expanding CD8⁺cytotoxic T cells in healthy tissues, inflammation and the cancer microenvironment. , 2020, , .		0
399	Abstract 2735: Clinical significance of CD4+CD7âˆ’helper T-cells and tumoral CD7 expression in colorectal cancer. , 2021, , .		0
400	Abstract 2833: Mesothelin expression in human tumor types: a tissue microarray study on more than 13,000 tumor samples. , 2021, , .		0
401	Abstract 2773: Deep profiling of the PD-1/PD-L1 pathway in 10000 cancers revealed changes in the immune cell composition between cancer entities. , 2021, , .		0
402	Abstract 2775: PD-L1 expression in human tumors: a tissue microarray study on 5,561 tissue samples and 87 tumor types. , 2021, , .		0
403	Abstract 2750: Prognostic impact of tumor infiltrating lymphocytes in the tumor microenvironment of vulvar squamous cell carcinoma. , 2021, , .		0
404	P02.06â€¦Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. , 2021, , .		0
405	P02.03â€¦Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers. , 2021, , .		0
406	Prognostic Molecular Features in Diffuse Large B-Cell Lymphoma from Saudi Arabia.. Blood, 2004, 104, 4609-4609.	0.6	0
407	Epstein-Barr Virus Infection Is Not the Sole Cause of High Prevalence for Hodgkinâ€™s Lymphoma in Saudi Arabia.. Blood, 2004, 104, 3120-3120.	0.6	0
408	Association of nuclear accumulation of p53 with ERG fusion and poor prognosis in prostate cancer.. Journal of Clinical Oncology, 2012, 30, 124-124.	0.8	0
409	The combination of DNA ploidy status and PTEN/6q15 deletions to provide strong and independent prognostic information in prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5027-5027.	0.8	0
410	Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. American Journal of Clinical Pathology, 2021, 156, S137-S138.	0.4	0
411	Abstract P068: Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers. , 2022, , .		0
412	Abstract P069: Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. , 2022, , .		0
413	Immune phenotypes and T-cell density at the invasive margin correlate with prognosis in epithelial vulvar cancer.. Journal of Clinical Oncology, 2022, 40, 5599-5599.	0.8	0